This value can be determined using imaging measurements or any other measure of tumor burden, such as PSA values for patients with prostate cancer.14,15,16 Since tumors that decrease do not cause mortality, the rate at which the treatment-sensitive fraction that will be eliminated regresses or decays (d) has no impact on overall survival. The gene discussed is KLK3; the disease is prostate carcinoma.